Researchers created TPA, a combined targeted peptide that inhibited the PD-1/PD-L1 axis, activated p53, and showed tumor killing and immunotherapeutic sensitization effects on a humanized PBMC-engrafted PDX model. This evidence concerns the gene TP53 and neoplasm.